Back to top
more

Xeris Pharmaceuticals (XERS)

(Delayed Data from NSDQ)

$1.75 USD

1.75
932,971

0.00 (0.00%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $1.75 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Xeris Pharmaceuticals (XERS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -32.26% and -11.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Xeris Pharmaceuticals (XERS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 3.23% and 6.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals (XERS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -5.13% and -22.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals (XERS) is Overbought: Is A Drop Coming?

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Do Options Traders Know Something About Xeris Pharmaceuticals (XERS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Xeris Pharmaceuticals (XERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 35.19% and 111.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.

Xeris Pharmaceuticals (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Xeris Pharmaceuticals (XERS) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.

Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 11.27% and -11.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher

by Zacks Equity Research

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Company News for May 26, 2020

by Zacks Equity Research

Companies In The News Are: TTWO, XERS, SPLK, NAVB

Xeris Pharmaceuticals Inc (XERS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Xeris' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Xeris Pharmaceuticals.

Eiger Completes NDA Submission of Progeria Drug Lonafarnib

by Zacks Equity Research

Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.

Xeris Pharmaceuticals, Inc. (XERS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Xeris Pharmaceuticals, Inc. (XERS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris Pharmaceuticals, Inc. (XERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 3.17% and 61.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Xeris Pharmaceuticals, Inc. (XERS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of -31.96% and 57.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.